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Purpose: To determine the genetic and genomic alterations underlying classic aniridia in Saudi Arabia, a region with
social preference for consanguineous marriage.
Methods: Prospective study of consecutive patients referred to a pediatric ophthalmologist in Saudi Arabia (2005–2009).
All patients had paired box gene 6 (PAX6) analysis (sequencing and multiplex ligation-dependent probe amplification
analysis if sequencing was normal). If PAX6 analysis was negative, the following were performed: candidate gene
sequencing (forkhead box C1 [FOXC1], paired-like homeodomain transcription factor 2 [PITX2], cytochrome P450,
family  1,  subfamily  B  [CYP1B1],  paired-like  homeodomain  transcription  factor  3  [PITX3],  and  v-maf  avian
musculoaponeurotic fibrosarcoma oncogene homolog [MAF]) and molecular karyotyping by array competitive genomic
hybridization (250K single nucleotide polymorphism (SNP) arrays).
Results: All 12 probands (4 months – 25 years of age; four boys and eight girls) had lens opacity and foveal hypoplasia
in addition to no grossly visible iris. Four cases were familial. All cases were products of consanguineous unions except
for three, one of which was endogamous. Heterozygous PAX6 mutations (including two novel mutations) were detectable
in all but two cases, both of which were sporadic. In one of these two cases, the phenotype segregated with homozygosity
for a previously-reported pathogenic missense FOXC1 variant (p.P297S) when homozygosity for chromosome 11q24.2
deletion (chr11:125,001,547–125,215,177 [rs114259885; rs112291840]) was also present. In the other, no genetic or
genomic abnormalities were found.
Conclusions: The classic aniridia phenotype in Saudi Arabia is typically caused by heterozygous PAX6 mutations, even
in the setting of enhanced homozygosity from recent shared parental ancestry. For PAX6-negative cases, interaction
between missense variation in an anterior segment developmental gene and copy number variation elsewhere in the genome
may be a potential mechanism for the phenotype.
Classic aniridia (OMIM 106210) is a panocular disorder
which,  in  addition  to  lack  of  grossly  visible  iris,  is
characterized  by  keratopathy,  lens  opacity,  juvenile-onset
glaucoma, foveal hypoplasia, and optic nerve hypoplasia [1].
This classic phenotype is caused by heterozygous mutation in
the ocular developmental gene paired box gene 6 (PAX6;
OMIM  *607108;  11p13),  typically  through
haploinsufficiency [2]. For cases in which the contiguous gene
Wilms  tumor  1  (WT1;  OMIM  194070;  11p13)  is  also
disrupted, affected children are typically syndromic and at risk
for juvenile Wilms tumor of the kidney (WAGR syndrome,
OMIM  194072)  [3].  Previous  studies  have  shown  that
dominant PAX6 mutations are the only known cause of classic
aniridia.  However,  even  with  comprehensive  analysis  of
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PAX6 including copy number analysis, up to 10% of classic
anirida cases have no identifiable mutation [2,4].
Congenital iris abnormality in general can also be due to
heterozygous PAX6 mutation but is both phenotypically and
genotypically more heterogenous. Heterozygous mutation in
the ocular developmental gene forkhead box C1 (FOXC1;
OMIM  *601090;  6p25)  or  paired-like  homeodomain
transcription factor 2 (PITX2; OMIM *601542; 4q25-q26)
causes  the  Axenfeld-Rieger  spectrum  (OMIM  602482,
180500, 137600), an anterior segment dysgenesis which can
include mild iris stromal hypoplasia, corectopia, polycoria,
iris pigment border hyperplasia (“ectropion uvea”), and/or
virtually complete lack of iris [5]. FOXC1 duplication can
cause the phenotype as well [6,7]. Affected children have a
propensity  for  congenital  or  juvenile  glaucoma,  can  have
neural  crest-related  non-ocular  findings  (e.g.,  maxillary
hypoplasia,  dental  anomalies),  and  can  show  significant
intrafamilial phenotypic variation for the same mutation [5,
8,9]. Congenital iris abnormality can also occur in the setting
of  congenital  glaucoma  from  homozygous  or  compound
heterozygous  mutations  in  cytochrome  P450,  family  1,
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708subfamily B (CYP1B1; OMIM *601771; 2p22-p21) [10], in
the setting of anterior segment mesenchymal dysgenesis due
to  heterozygous  mutation  in  paired-like  homeodomain
transcription factor 3 (PITX3; OMIM +602669; 10q25) [11],
and  in  the  setting  of  anterior  segment  dysgenesis  due  to
heterozygous mutation in v-maf avian musculoaponeurotic
fibrosarcoma  oncogene  homolog  (MAF;  OMIM  *177075;
16q22-q23) [12]. The variation in iris phenotype for a given
mutation that has been observed in FOXC1-related disease as
well as in other genetic causes of congenital iris abnormality
is likely related to the influence of yet unidentified modifiers.
Although a small percentage of aniridia cases have no
detectable PAX6 mutation, to the best of our knowledge no
other genotype has been associated with the classic aniridia
phenotype.  We  propose  two  potential  causes  for  PAX6-
negative classic anirida: 1) genomic alteration that affect cis
or trans regulatory elements of PAX6, or 2) point mutations
or  deletions  in  other  genes  known  to  be  involved  in  the
pathogenesis of congenital iris abnormalities. Genome-wide
copy number analysis of classic aniridia cases with negative
PAX6  sequencing  can  investigate  the  first  possibility.  In
addition to interrogation for genomic alteration in a genome-
wide  fashion,  this  would  also  further  characterize  PAX6
deletions. Regarding the second possibility, i.e., mutations in
other known genes, gross deletions would also be uncovered
by  genome-wide  copy  number  analysis  while  sequencing
variants can be investigated by direct sequencing of a panel
of genes known to cause congenital iris abnormalities when
mutated.  Moreover,  if  recessive  mutation  in  other  known
genes can cause classic aniridia, this would most likely be
uncovered by the study of affected consanguineous families,
for whom a recessive cause is more likely to be found if a
recessive cause for the phenotype exists [13]. In the current
study, we analyze the underlying genotype of classic aniridia
in mostly consanguineous patients by PAX6 analysis and, for
PAX6-negative cases, by candidate gene sequencing and array
genomic copy number variation analysis.
METHODS
Institutional  review  board  approval  was  obtained  for  this
study (KFSHRC IRB #2070023
KKESH IRB #?????). Consecutive patients with classic
aniridia referred to the pediatric ophthalmology service of one
of the authors (A.O.K.) from 2005 to 2009 were prospectively
enrolled in the study. Classic anirida was defined as no grossly
visible iris in addition to keratopathy, lens opacity, and/or
foveal  hypoplasia  [1].  Patients  underwent  complete
ophthalmic  examination  and  venous  blood  sampling  for
analysis. The strategy for genetic and genomic analysis was
as follows: If direct sequencing did not reveal PAX6 mutation,
multiplex  ligation-dependent  probe  amplification  (MLPA)
was  performed  to  assess  for  PAX6  deletions.  If  this  was
normal,  the  candidate  genes  FOXC1,  PITX2,  CYP1B1,
PITX3,  and  MAF  were  sequenced.  In  addition,  genomic
molecular  karyotyping  was  performed  via  array-based
comparative genomic hybridization (array CGH) in all cases
that lacked an identifiable PAX6 mutation. When available
and appropriate, relatives underwent ophthalmic examination
and venous blood sampling for confirmatory genetic analysis.
DNA  extraction:  Genomic  DNA  was  extracted  from
whole blood anti-coagulated with EDTA using the Purgene
Gentra DNA Extraction Kit (Cat. # D-5000; Gentra Systems,
Minneapolis,  MN)  according  to  the  manufacturer’s
instructions. The DNA was quantified spectrophotometrically
and stored in aliquots at −20 °C until required.
PCR  amplification  and  DNA  sequencing:  PCR
amplification was performed on a thermocycler (DNA Engine
Tetrad, MJResearch, Inc., Hercules, CA) in a total volume of
25 µl, containing 10 ng DNA, 50 mM KCl, 10 mM Tris-HCl
(pH 9.0), 1.5 mM MgCl2, 0.1% Triton X-100, 0.25m M of
each dNTP, 0.8 µM of each primer and 0.5 Units of Taq
polymerase  (D-40724;  QIAGEN,  Hilden,  Germany).  For
PCR, an initial denaturation step at 95 °C for 10 min was
followed by 40 cycles of denaturation at 95 °C for 30 s,
annealing at 59 °C for 30 s and extension at 72 °C for 30 s
followed  by  a  final  extension  step  of  72  °C  for  10  min.
Genomic  DNA  of  each  patient  was  screened  for  coding
regions and boundary site variants by sequencing reactions
using BigDye® Terminator v 3.0 (Applied Biosystems, Inc.,
Foster City, CA). Following the manufacturer’s instructions,
sequencing  reactions  were  desalted  and  unincorporated
nucleotides  removed  using  ethanol  precipitation  and  re-
suspended in a deionized distilled water for injection on a
Applied  Biosystems  3730xl  DNA  Analyzer  (Applied
Biosystems, Inc.). Sequence analysis was performed using the
SeqManII module of the Lasergene (DNA Star Inc., Madison,
WI)  software  package  and  was  compared  to  the  relevant
reference sequence.
MLPA analysis: MLPA analysis of PAX6 was performed
using  the  commercial  Kit  P219  PAX6  (MCR  Holland,
Amsterdam,  The  Netherlands).  The  manufacturer’s
instructions  were  followed  and  data  was  analyzed  using
Coffalyser software (MCR Holland).
Molecular  karyotyping:  Affymetrix  Genechip  Human
Mapping 250K SNP arrays (Affymetrix, Santa Clara, CA)
were  used.  All  procedures  were  performed  according  to
Affymetrix standard protocols. The SNP call rate and sample
mismatch  report  was  determined  with  GTYPE  software
(Affymetrix). Two algorithms, the Affymetrix® Genotyping
Console™ and Copy Number Analyzer for GeneChip® arrays
(CNAG) Version 3.021 software were used to infer copy
number variation among affected individuals based on the
hybridization intensity signal of the probes.
RESULTS
Twelve probands (four familial, eight sporadic) were included
in the study – four boys and eight girls who ranged from 4
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709months to 25 years of age. Two of the familial cases were
previously-reported  [14].  All  patients  were  products  of
consanguineous unions except for three cases, one of which
was endogamous. None had associated non-ocular congenital
malformation or complicated birth history and all had had
comprehensive physical examination by a pediatrician. All
probands had lens opacity, foveal hypoplasia, and gross lack
of iris; in addition, all probands had keratopathy except for
two sporadic cases (patients 7 and 12 in Table 1). All four
familial cases and six of the eight sporadic cases had PAX6
mutation,  including  two  novel  PAX6  mutations  (Table  1,
Figure  1,  and  Figure  2).  The  two  sporadic  cases  without
detectable PAX6 mutation (patients 7 and 9 in Table 1), both
from consanguineous families, are discussed further below.
Patient 7 (Figure 3) had classic aniridia in that in addition
to lack of iris she had lens opacity and foveal hypoplasia. She
had  normal  genetic  and  genomic  analysis;  no  underlying
cause was found for the ocular phenotype.
Patient 9 (Figure 4) had classic aniridia in that in addition
to lack of iris she had keratopathy, lens opacity, and foveal
hypoplasia. She was homozygous for a missense variant in
FOXC1  (p.P297S)  that  was  previously  been  reported  as
pathogenic and as a cause for dominant anterior segment
dysgenesis in two unrelated individuals [15]. However, her
father was heterozygous for the variant while her mother was
homozygous and neither parent had significant ophthalmic
findings despite careful clinical ophthalmic examination with
attention  to  the  anterior  segment  and  fovea.  Molecular
karyotyping  revealed  homozygosity  (nullizygosity)  for  a
chromosome  11q24.2  deletion  (chr11:125,001,547–
125,215,177 [rs114259885 and rs112291840]) present in the
child and heterozygosity (hemizygosity) for the deletion in
both  parents.  Thus  the  child's  phenotype  segregated  with
homozygosity for the FOXC1 missense variant in conjunction
with homozygosity for the deletion (Figure 4). The region of
this deletion contains five genes (CHK1 checkpoint homolog
[CHEK1], acrosomal vesicle protein 1 [ACRV1], prostate and
testis  expressed  4  [PATE4],  prostate and testis expressed 2
[C11ORF38],  and  FLJ41047),  none  of  which  has known 
ocular  function.   Neither  the   FOXC1  variant  nor  the
deletion was found in 100 ethnically-matched controls.
DISCUSSION
In this series of classic aniridia in mostly consanguineous
families from Saudi Arabia, the heterozygous PAX6 mutation
was detected in 4/4 familial cases and 6/8 sporadic cases. One
PAX6-negative  case  harbored  homozygosity  for  both  a
previously-reported pathogenic missense FOXC1 variant and
for a deletion on chromosome 11q24.2; the unaffected parents
were heterozygous or homozygous for the FOXC1 variant and
both were heterozygous for the deletion. The other PAX6-
negative  case  remained  idiopathic  despite  candidate  gene
sequencing and whole genome copy number analysis.
Studies of consanguineous families are more likely to
uncover a recessive cause for a given phenotype if a recessive
cause exists because of parental shared recent ancestry. Every
individual is a heterozygous carrier for mutated alleles that
would potentially cause recessive disease in the homozygous
(or compound heterozygous) state. Consanguineous marriage
increases the expression of rare recessive disease because
unless carriers are related, they are unlikely to marry a partner
who carries the same disorder [16]. In the current study of
classic aniridia of mostly inbred families, 3/3 familial cases
from consanguineous families and 6/8 sporadic cases from
consanguineous  or  endogamous  families  harbored
heterozgyous PAX6 mutation. Thus even in the setting of
enhanced homozygosity from recent shared parental ancestry,
heterozgyous  PAX6  mutation  typically  underlies  the
phenotype of classic aniridia.
Two patients, both from consanguineous families, had no
detectable PAX6 mutation. Although no genetic or genomic
cause for classic aniridia was found in one (Patient 7, Figure
3), in the other (Patient 9, Figure 4) there was a homozygous
FOXC1 missense variant previously reported as responsible
for  anterior  segment  dysgenesis  in  the  heterozygous  state
[15]. However, both unaffected and otherwise normal parents
of the patient harbored this variant – in the heterozygous state
in the father and in the homozygous state in the mother – and
both  unaffected  parents  had  no  significant  ophthalmic
findings.  Additional  analysis  by  array  CGH  revealed  a
homozygous deletion in the child on chromosome 11q24.2
that was present in the heterozygous state in both parents. One
can speculate that either the homozygous 11q24.2 deletion
alone or in concert with the homozygous FOXC1 missense
variant was associated with the classic aniridia phenotype.
The latter seems more plausible as the genes affected by the
deletion do not have known ocular function while p.P297S
FOXC1 has been previously described as pathogenic [15].
Functional  work  suggests  that  p.P297S  FOXC1  alters
interaction with other yet unidentified factors involved in
FOXC1 transactivation and degradation, thus extending the
half-life of the protein and causing an increased dosage effect
akin to the mechanism of FOXC1 duplication [15]. Consistent
with this, cases associated with p.P297S FOXC1 as well as
those associated with FOXC1 duplication have been reported
with phenotypes of iridogoniodysgeneis that can resemble the
iris appearance of patients with classic anirida [15,17]. While
the  genes  contained  within  this  11q24.2  deletion  are  not
known to be involved in eye development, such a role has not
been excluded. In addition, we cannot exclude the possibility
that  non-coding  regulatory  elements  for  PAX6  may  exist
within this region. Either of these two hypothesized causal
links could be either sufficient or dependent on the FOXC1
mutation. Patient 9 also had developmental delay, which may
or  may  not  have  been  related  to  the  deletion  alone  or  in
combination with p.P297S FOXC1.
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711For a particular mutation in a given gene, differences in
a given individual's background genotype and environmental
exposure  cause  intrafamilial  phenotypic  variability.
Intrafamilial phenotypic variability has been well documented
for FOXC1-related disease [5,9]. Background genomic copy
number variation – both deletion and repeats – can increase
susceptibility to ocular disease and contribute to phenotypic
variability [18,19]. In patient 9 from this study (Figure 4), the
homozygous  deletion  may  have  been  responsible  for  the
expression  of  a  p.P279S  FOXC1-related  anterior  segment
phenotype,  i.e.,  the  homozygous  deletion  is  a  genomic
explanation for the intrafamilial phenotypic variability and the
observed classic aniridia in patient 9. Although there have
been  reports  of  lack  of  visible  iris  in  patients  with
heterozygous FOXC1 [20] as well as heterozygous PITX2
[21] mutations, these previously-reported patients would not
be considered classic aniridia as they did not have documented
keratopathy, lens opacity, or foveal hypoplasia. In addition,
the  previously-reported  patient  [20]  with  lack  of  iris  and
heterozgyous FOXC1 mutation also had obvious newborn
glaucoma, which is not part of classic aniridia [10]. There is
a  previous  report  of  gross  lack  of  iris  and  concurrent
keratopathy associated with heterozygous FOXC1 mutation;
this was in a baby boy who also had severe newborn glaucoma
Figure  1.  Patient  2,  without
pharmacologic  mydriasis.  A:
Retroillumination shows lack of iris and
the lenticular changes (left eye shown).
B: Diffuse illumination reveals surface
keratopathy (left eye shown). C: There
was  no  defined  fovea  by  indirect
ophthalmoscopy  (left  eye  shown).  D:
sequencing  revealed  a  novel  PAX6
mutation (p.E185EfsX14).
Figure  2.  Patient  6,  without
pharmacologic  mydriasis.  A:  Slit
illumination  revealed  surface  limbal
keratopathy (right eye shown). B: Slit
illumination  shows  lack  of  iris  and  a
posterior  lenticular  opacity  (right  eye
shown). C: The fovea is not well defined
(right  eye  shown).  D:  sequencing
revealed  a  novel  PAX6  mutation
(p.Q350X).
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712[22]. Again, his phenotype would not be considered classic
aniridia because of newborn glaucoma [10].
Our finding of a homozygous deletion of a previously
unreported  copy  number  variation  in  a  patient  with  this
phenotype  could  be  interpreted  as  a  rare  recessive  form.
However, this case has to be viewed in the context of the
FOXC1 mutation and lack of other siblings in whom we can
verify the segregation pattern of this deletion with respect to
the classic aniridia phenotype. In other words, we caution
against the over-interpretation of this finding as an example
of a recessive form of aniridia at this time. It is hoped that our
ongoing analysis of more classic aniridia cases in our highly
consanguineous  population  will  address  this  possibility.
Future studies with even higher resolution microarrays are
needed to further investigate the potential role of genomic
copy number variation in classic aniridia patients without
PAX6 mutations.
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